VK2809 said it had great success in Investing.com’s NASH management and inheritance study

SAN DIEGO – Viking Therapeutics, Inc. (NASDAQ: VKTX) has conducted a positive Phase 2b study with VK2809 in the treatment of no-alcohol steatohepatitis (NASH), which can lead to metabolic dysfunction-related steatohepatitis (MASH), which can occur. The study study was published at 75. Liver Meeting® 2024 of the American Association for the Study of Liver Diseases presented.

The data from the VOYAGE study showed a significant reduction in life expectancy once in 52 years. The patients pay a small relative compensation of between 37% and 55%. The answer, defined as the earlier patients with a reduction in disease burden of ≥30%, was in the range of 52% to 64% and 88% and the war would become German as a placebo.

When the end of the procedure is performed, the display of NASH or the fibrosis rash will be displayed, so that the fibrosis extension by NASH is shown. With the VK2809 patients discussed, the NASH resolution rates remained 63% and 75%, while the fibrosis resolution rates were 44% and 57%. Darüber shows that 44% of patients regard a NASH relief as a fibrosis improvement.

The research on the reduction of LDL-C (20% to 25%) and other atherogenic proteins has shown a potent cardioprotective effect on VK2809. The Security and Verträglichkeitsprofil von VK2809 war has changed, because the treatment of the lungs is mild or moderate insufficiency.

Dr. Rohit Loomba, chief of gastroenterology and hepatology at UC San Diego School of Medicine, elaborated on the therapeutic potential of VK2809 and proved that it leads to “strong reduction in liver disease, reduced NASH treatment and treatment of fibrosis” .

Brian Lian, Ph.D., CEO of Viking, has an overview of the Beitrags of VK2809 in the Pipeline Program of the Unternehmens for Stoffwechselerkrankungen. The VOYAGE study is a randomized, double-blind, placebo-controlled trial of patients with biopsy-best results of NASH/MASH and fibrosis, examining their investigation, certainty and treatment of VK2809.

VK2809 is a leberspecific thyroid hormone beta agonist, which reduces and improves the lipid profile, benefiting patients with NASH/MASH and potent metabolic disease.

This message is based on a press conference by Viking Therapeutics.

In others, Viking Therapeutics are active in conducting clinical trials, including Laidlaw, Jefferies and BTIG in their Kaufempfehlungen for the investigations imposed by the internal court. Viking Therapeutics reported a net surplus of US$24.9 million for the quarter of 2024, with research and development costs of US$22.8 million and all operating and sales costs of US$13.8 million. The fact that the liquidity of the economy could be solved with US$930 million and a barmitteln and equivalent liquidity was a tough clinical study.

Viking Therapeutics’ Wirkstoff candidate VK2735, which works for the company’s weight management, has achieved some very good results in several years of research. High doses of VK2735 after four weeks can cause significant weight loss in gastrointestinal digestion. Drug trial results from a Phase 2a trial in four quarters of 2024 have been completed.

Analysts from Laidlaw, Jefferies and BTIG have probably examined the drugs and medications that have given VK2735 Viking a legal position in the adiposity treatment market. Darüber hinaus plant Viking, VK2735 in phase 3 voranzutreiben and a phase 2 study into adiposity einzuleiten. These young people can underscore the strength of Viking Therapeutics in the field of obesity medications.

InvestingPro Acknowledgment

The positive research from Viking Therapeutics’ Phase 2b trial for VK2809 in the treatment of NASH/MASH has positively impacted the financial perspective of our external partners. Laut InvestingPro-Daten entered Viking’s market capitalization at 5.72 Billion US-Dollar, investors’ optimism reflected more broadly the potential of foreign economies in the lucrative NASH market.

Most clinical treatments are very effective, but Viking Therapeutics is not profitable. InvestingPro Tips says that the companies will not have a profitable war in the future and analysts cannot make a profitable profit these years. This is typical of development-stage biotech companies, which invest mainly in research and clinical studies.

Viking’s financial layer is said to be stable. One InvestingPro tip that gave us more money as debt in the Bilanz era was for financing financing and potential market developments. As the liquidation of Viking had ended due to the short-term profits, the flexibility was financed at the Weiterentwicklung beneficiary Pipeline.

The Kursentwicklung der Aktie War in Letzter Zeit volatil. InvestingPro-Daten indicate a return of 18.96% in the past week and a return of 25.36% in the month. The strong point is that the termination rate of 335.76% over the years and the potential for healthy Kursschwankungen at Biotech-Aktien, which are based on clinical study activities and the market immune basis, are shown.

Although Viking Therapeutics was trading with a high price book of $6.28, it was clear that the Wachstumserwartungen in the Aktienkurs was one of the most important things. The companies did not see a dividend, but were in favor of the most oriented Biotech companies, who reinvest in their pipeline.

For those things that have a different relationship Analyze interests, bitet InvestPro 12 other tips for Viking Therapeutics, one of the best tips for healthcare financing and the market position of the Unternehmens.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.